Personalized medicine: Hype or reality

Oncologist

Volumn 18, Issue 6, 2013, Pages 640-643

  Chabner, Bruce A ^a   Ellises, Leif W ^a   John Iafrate, A ^b  

^a Department of Medicine ^*  (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER GENETICS; EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; GENOTYPING TECHNIQUE; HUMAN; MELANOMA; NEOPLASM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT;

HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84879493413     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0210     Document Type: Editorial

References (24)

1. Slamon DF, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344: 783792.
2. Demetri GD, Margaret von Mehren, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347;472-280.
3. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-4817.
4. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-19New drugs
5. Kwak AL, Bang Y-J, Camidge R et al. N Eng J Med 2010;363:1693-703.
6. http://www.fda.gov/drugs/lnformationon-drugs/Approved
7. Rudon J, Saura C, Dienstmann R et al. Molecular prescreening to select patient population in early clinical trials. Nat. Rev Clinical Oncol 2012; 1038/nrclinonc. 2012.48.
8. Ou S-H, Bartlett CH, Mino-Kenudson M et. al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. The Oncologist 2012; 17:1351-1375.
9. Arcila M, Lau C, Nafa K et al. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011;13:64-73.
10. Bergethon K, Shaw AT, Ou S-H I et al. ROS1 Rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 35: 6345, Epub 2012 Jan 3.
11. Pentheroudakis G, Kotoula V, De Roock W et. al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer; interaction of EGFR ligand expression with RAS/RAF, PI3KCAgenotypes. BMC Cancer 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.
12. Hartocollis, Anemona. Cancer centers racing to map patients' genes. New York Times. Published April 21, 2013. Available at http:// www.nytimes.com/2013/0 4/22/health/ patients-genes-seen-as-future-of-cancer-care. html?pagewanted=all&_r=0. Accessed June 3, 2013.
13. Shaw A, Kim D-W, Nakagawa K et. al. Crizotinib versus chemotherapy in advanced ALK-rear-ranged lung cancer. N Engl J Med doi
14. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;24:2380-8.
15. The Northern Ireland Molecular Pathology L aboratory. Available at https://vimeo. com/55830092. Accessed June 3, 2013.
16. Hollmer, Mark. U.K.'s NHSdebuts multi-gene sequencing cancer Dx. http://www.fiercemedi-caldevices.com/story/uk-nhs-debuts-multi-gene-sequencing-cancer-dx. Published March 26, 2013. Accessed June 3, 2013.
17. Butler, Declan. France puts €260 million into research infrastructure. Nature. Published online 8 March 2011. Available at: http://www.nature. com/news/2011/110308/full/news.2011.145.html. Accessed June 3, 2013.
18. German Cancer Research Center. Joining forces against cancer-German consortium for translational cancer research gets started. Published April 15, 2011. Available at: http://www. dkfz.de/en/presse/pressemitteilungen/2011/ dkfz-pm-11-24-German-Consortium-for-Trans-lational-Cancer-Research-Gets-Started.php. Accessed June 3, 2013.
19. Cancer Prevention and Research Institute of Texas. Available at: http://www.cprit.state.tx.us. Accessed June 3, 2013.
20. Copelin, Laylan. CPRIT fallout: Cancer network ceases operations. Published January 29, 2013. Available at: http://www.statesman.com/ news/business/cprit-fallout-clinical-trials-net-work-suspends-ope/nT9SH/. Accessed June 3, 2013.
21. Bang Y-J, Van Cutsem E, Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esopha-geal junction cancer (To GA): a phase 3, open-label randomized controlled trial. Lancet 2010;376, 687-697.
22. Lynch TJ, Bell DW, Sondella R, et. al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
23. Jiang X, Zhou J, Yuen NK, et. al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008; 14: 7726-32.
24. Cortes JE, Kantarjian H, Shah NP, et. al. Pona-tinib in refractory Philadelphia chromosome-positive leukemias. N Engl J. Med 2012; 367;2075-2088.